EC-NAPROSYN (naproxen) by Hamilton medical is cyclooxygenase inhibitors [moa]. First approved in 1994.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
EC-NAPROSYN is a delayed-release oral tablet formulation of naproxen, a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for the treatment of various pain and inflammatory conditions, with the delayed-release formulation designed to reduce gastrointestinal irritation.
As LOE approaches, the commercial team is likely optimizing for profitability and managing market erosion from generics rather than growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain
A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain
Worked on EC-NAPROSYN at Hamilton medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on EC-NAPROSYN offers exposure to mature product management and generic defense strategies in a highly competitive NSAID market. Career growth is likely limited by the product's LOE trajectory, making it best suited for professionals seeking operational efficiency experience or looking for a stable, lower-intensity portfolio assignment.